These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10894352)

  • 1. Role of natural killer cells in the development of graft-versus-host disease.
    Bryson JS; Flanagan DL
    J Hematother Stem Cell Res; 2000 Jun; 9(3):307-16. PubMed ID: 10894352
    [No Abstract]   [Full Text] [Related]  

  • 2. Allogeneic hematopoietic transplantation and leukemia: a second chance for T cells?
    Kuppen PJ
    Transplantation; 2008 Jan; 85(1):7-8. PubMed ID: 18192904
    [No Abstract]   [Full Text] [Related]  

  • 3. Natural killer cell therapy for cancer: delivering on a promise.
    Shook DR; Leung W
    Transfusion; 2013 Feb; 53(2):245-8. PubMed ID: 23384099
    [No Abstract]   [Full Text] [Related]  

  • 4. MPO is a potential biomarker of acute graft-versus-host disease.
    Ge B; Ye H
    Biomark Med; 2013 Jun; 7(3):391-3. PubMed ID: 23734800
    [No Abstract]   [Full Text] [Related]  

  • 5. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
    Liu YP; Li Z; Nador RG; Strober S
    Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular graft-versus-host disease: a review.
    Shikari H; Antin JH; Dana R
    Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic PBPC transplantation: an effect on incidence and distribution of chronic graft-versus-host disease without long-term survival benefit?
    Snowden JA; Nivison-Smith I; Atkinson K; Fay K; Concannon A; Dodds A; Milliken S; Biggs J
    Bone Marrow Transplant; 2000 Jan; 25(1):119-20. PubMed ID: 10654027
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute graft-versus-host disease following hematopoietic stem-cell transplantation.
    Hu SW; Cotliar J
    Dermatol Ther; 2011; 24(4):411-23. PubMed ID: 21910799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.
    Hosseini E; Schwarer AP; Ghasemzadeh M
    Iran J Allergy Asthma Immunol; 2012 Mar; 11(1):15-21. PubMed ID: 22427472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in graft-versus-host disease.
    Chao NJ
    J Hematother Stem Cell Res; 2000 Jun; 9(3):295-6. PubMed ID: 10894349
    [No Abstract]   [Full Text] [Related]  

  • 12. Cellular mechanism for granulocyte-colony stimulating factor in the prevention of graft-versus-host disease in combined bone marrow and peripheral blood transplantation for hematological malignancies: the composition in collection.
    Zhang C; Zhang X; Chen XH
    Transfus Apher Sci; 2013 Feb; 48(1):3-9. PubMed ID: 23279971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PBSCT and GVHD].
    Hino M; Yamane T; Ohta K; Tatsumi N
    Rinsho Byori; 1999 May; Suppl 110():92-8. PubMed ID: 10475037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of graft-versus-host disease by naturally occurring regulatory T cells.
    Zeng D; Lan F; Hoffmann P; Strober S
    Transplantation; 2004 Jan; 77(1 Suppl):S9-S11. PubMed ID: 14726761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Indication of bone marrow transplantation].
    Masaoka T
    Rinsho Byori; 1995 Jul; Suppl 99():1-7. PubMed ID: 7474413
    [No Abstract]   [Full Text] [Related]  

  • 16. Alveolar hemorrhage and acute graft-versus-host disease.
    Ratajczak P; Desveaux A; Socié G; Janin A
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1244-5. PubMed ID: 17889362
    [No Abstract]   [Full Text] [Related]  

  • 17. Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.
    Martínez-Bravo MJ; Calderón-Cabrera C; Márquez-Malaver FJ; Rodríguez N; Guijarro M; Espigado I; Núñez-Roldán A; Pérez-Simón JA; Aguilera I
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1356-62. PubMed ID: 24844856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of late complications after allogeneic hematopoietic stem cell transplantation].
    Kurosawa S; Fukuda T
    Rinsho Ketsueki; 2013 Feb; 54(2):167-76. PubMed ID: 23470823
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of adenotonsillectomy in graft-versus-host disease.
    Schwab B; Raynor E
    Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):57-60. PubMed ID: 22018926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo selection of recipient-type alloantigen-specific CD4(+)CD25(+) immunoregulatory T cells for the control of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
    Trenado A; Fisson S; Braunberger E; Klatzmann D; Salomon BL; Cohen JL
    Transplantation; 2004 Jan; 77(1 Suppl):S32-4. PubMed ID: 14726768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.